VBL Therapeutics shares (NASDAQ:VBLT) plummeted 65.5 percent Tuesday to $4.87, more than a dollar under the company's recent initial public offering (IPO) price, as investors digested news that VB-201, an experimental autoimmune therapy that had appeared to help patients with psoriasis in an earlier midstage study, failed to significantly benefit both psoriasis and ulcerative colitis sufferers in separate phase II trials. Read More
Formerly known as Chanrx Corp., Laguna Pharmaceuticals Inc. raised $30 million in series B money for phase III work in atrial fibrillation (AF) and atrial flutter with vanoxerine, moving operations from Cleveland to San Diego while bringing aboard as CEO well-known biotech player Bob Baltera. Read More
SAN JOSE, Calif. – The push to develop vaccines and antivirals against Ebola must go on, even though the falling infection rate may reduce the chances of getting definitive phase III efficacy data during the current outbreak. Read More
SAN JOSE, Calif. – The industry's expensive attempts to develop treatments for Alzheimer's disease have been confounded by the difficulties of diagnosis, and multiple drugs targeting amyloid plaques, administered once overt symptoms are well established, have failed in development. Read More
SAN JOSE, Calif. – As momentum increases behind the movement for greater transparency of clinical trials data, attention is turning to ensuring that when information is made available it is accessible and consistent, and that confidentiality is respected when patient-level data are disclosed. Read More
HONG KONG – In the wake of a pair of deals in just two months that would expand its European footprint, Chinese biopharmaceutical company 3SBio Inc. is getting ready for an initial public offering (IPO) in Hong Kong. Read More
HONG KONG – A highly potent small-molecule inhibitor designed by Korean scientists has been shown both in vivo and in vitro to be a promising candidate treatment for breast cancer that preferentially targets both breast cancer stem cells (BCSCs) and bulk tumor cells, thereby potentially reducing the chances of relapse. Read More
With 2015 shaping up as the year to reform the drug development and approval process, a raft of related legislation is floating through Congress. Read More
Ultragenyx Pharmaceutical Inc., of Novato, Calif., said underwriters of the previously disclosed offering of 3 million shares of common stock have exercised in full their option to purchase an additional 450,000 shares from the company at the public offering price of $54 each, before underwriting discounts. Read More
Cynata Therapeutics Ltd., of Melbourne, Australia, said earlier it has engaged an undisclosed contract research organization to begin clinical trial planning and logistics development for a phase I study of its mesenchymal stem cell product. Read More
Hyperion Therapeutics Inc., of Brisbane, Calif., said it amicably resolved its disputes, and entered a completion of phase III trial, option and mutual release agreement with Clal Biotechnology Industries Ltd. (CBI), of Ramat Gan, Israel, and Yeda Research and Development Co. Ltd. regarding Diapep277, a product candidate developed by Andromeda Biotech Ltd., a company which Hyperion acquired from CBI in June 2014. Read More
Eisai Inc., of Woodcliff Lake, N.J., said the FDA approved the company's receptor tyrosine kinase inhibitor Lenvima (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Read More
